| EN
Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.
Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.

Milestones

  • 1995

  • 2001

  • 2003

  • 2006

  • 2007

  • 2013

  • 2015

  • 2018

  • established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals

  • cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team

  • acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)

  • acquired a controlling interest in Shandong Simcere

  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE

  • completed the privatization

  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology

  • Shanghai R&D center established

  • established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
  • cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
  • acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)
  • acquired a controlling interest in Shandong Simcere
  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
  • completed the privatization
  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology
  • Shanghai R&D center established

Management Team

Ren Jinsheng

Chairman of the Board and
Chief Executive Officer

Tang Renhong, PhD

Executive Director of Simcere
Chairman of the Board and CEO of Simcere Zaiming

Wan Yushan

Executive Director and
Chief Financial Officer

Bijoyesh Mookerjee, MD

Chief Medical Officer, Oncology

Zhou Gaobo

Chief Investment Officer

Tamas Oravecz, PhD

Senior Vice President
CSO of Simcere, U.S.

Andrew Zhu

Senior Vice President

Danny Chen, PhD

Senior Vice President

Kevin Oliver, PhD

Senior Vice President

Song Wenjie

Senior Vice President of Simcere Zaiming

Mission

Providing Today’s Patients with Medicines of the Future

Core values

Integrity
Excellence
Perseverance
Proactivity
Customer-First

Simcere CI

  • The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
  • On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
  • The color green symbolizes life, health and vitality.